Neuro-SysMed Special Seminar with David Eidelberg, Head of the Center for Neurosciences at The Feinstein Institute for Medical Research, Manhasset, NY, United States. Title of the talk is “Metabolic Networks as Functional Biomarkers of Parkinson’s Disease.”
Time: Friday September 1, 2023 at 12.00-13.30
Place: Auditorium 2 at the BB-building
Registration: at this link.
Title of the talk: Metabolic Networks as Functional Biomarkers of Parkinson’s Disease
Coffee/tea will be available. All are welcome.
Speaker: David Eidelberg, MD, is head of the Center for Neurosciences at The Feinstein Institutes for Medical Research in Manhasset, New York. A neurologist and neuroscientist, he is widely known for his groundbreaking work on network dysfunction in neurological disorders including Parkinson’s disease, Huntington’s disease, dystonia and dementia.
He was first to identify metabolic networks as systems-level disease biomarkers in patients and has described previously unrecognized network pathologies. His automated computational approach is currently being used worldwide for the objective assessment of disease progression and treatment responses in individual patients and to enhance diagnostic accuracy.
His contributions have been recognized by the prestigious Fred Springer Award, the American Academy of Neurology Movement Disorders Research Award and the Bachmann Strauss Prize for Excellence in Dystonia. He is a member of the Association of American Physicians. Dr. Eidelberg received his medical training at Harvard, followed by postdoctoral fellowships at the National Hospital, Queen Square in London and Memorial Sloan Kettering Cancer Center in New York. He has authored more than 265 peer-reviewed original articles, 100 reviews and editorials, hundreds of scientific abstracts, and an edited volume (Imaging in Parkinson’s Disease, Oxford University Press, 2011). He serves on the editorial boards of several major journals and is editor-in-chief (Western Hemisphere) of Current Opinion in Neurology.
Research focus: Dr. Eidelberg directs a leading imaging research program in brain disease. Under his direction, the Center for Neurosciences has been internationally recognized for his work on the identification, characterization and assessment of pathological brain networks using functional imaging techniques. Using innovative computational algorithms, he and his team have used disease networks as quantitative imaging biomarkers for the early diagnosis of neurodegenerative disorders such as Parkinson’s disease, Huntington’s disease and Alzheimer’s disease. His group is currently studying the effects of treatment on these networks in patients receiving novel interventions for the disorders.
Abstract of the talk: Network analysis of functional brain scans acquired with [18F]-fluorodeoxyglucose positron emission tomography (FDG PET, to map cerebral glucose metabolism), or resting-state functional magnetic resonance imaging (rs-fMRI, to map blood oxygen level-dependent brain activity) has increasingly been used to identify and validate reproducible circuit abnormalities associated with neurodegenerative disorders such as Parkinson’s disease (PD). In addition to serving as imaging markers of the underlying disease process, these networks can be used singly or in combination as an adjunct to clinical diagnosis and as a screening tool for therapeutics trials. Disease-specific networks can also be used to measure rates of progression in natural history studies and to assess responses to symptomatic treatment or to potential disease modifying agents. Recent imaging studies in PD subjects scanned before and after treatment have revealed therapeutic effects beyond the modulation of established disease networks. Rather, other mechanisms of action may be at play, such as the induction of novel functional brain networks directly by treatment. To date, reproducible treatment-induced networks have been reported for established interventions such as deep brain stimulation (DBS) and novel therapeutic strategies such as subthalamic gene therapy and oral nicotinamide riboside (NR), and as a potential imaging marker of the placebo response. Indeed, changes in the expression of these networks with treatment have been found to correlate consistently with clinical outcome. Together, the data suggest a role for functional brain networks as treatment biomarkers in clinical trials for PD and other brain disorders.